1-3 of 3
Jim Stec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD
Journal: Blood
Blood (2004) 104 (11): 1386.
https://doi.org/10.1182/blood.V104.11.1386.1386
Published: 2004
Journal Articles

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Lenushka Maharaj, MSc, Sandra J. Strauss, MD, Jim Stec, Thomas A. Lister, Simon P. Joel, PhD
Journal: Blood
Blood (2004) 104 (11): 3294.
https://doi.org/10.1182/blood.V104.11.3294.3294
Published: 2004
Journal Articles

PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

James D. Cavenagh, MD, Rakesh Popat, MB BS, Nikki Curry, MB BS, Jim Stec, PhD, Treen C. Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David P. Schenkein, MD, Dixie-Lee Esseltine, MD, Heather Oakervee, MRCP
Journal: Blood
Blood (2004) 104 (11): 1478.
https://doi.org/10.1182/blood.V104.11.1478.1478
Published: 2004